Romaciclib

Romaciclib
Clinical data
Other names	RVU-120; SEL-120; SEL120-34; SEL120-34A
Identifiers
	IUPAC name 6,7-dibromo-5-methyl-2-piperazin-1-yl-1,3-diazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene;
CAS Number	1609522-33-9;
PubChem CID	73776233;
IUPHAR/BPS	13753;
DrugBank	DB18107;
ChemSpider	67886362;
UNII	6LGR0RYY5Q;
ChEMBL	ChEMBL4225966;
Chemical and physical data
Formula	C15H18Br2N4
Molar mass	414.145 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C2C3=C(CCCN3C(=N2)N4CCNCC4)C(=C1Br)Br;
	InChI InChI=InChI=1S/C15H18Br2N4/c1-9-11(16)12(17)10-3-2-6-21-14(10)13(9)19-15(21)20-7-4-18-5-8-20/h18H,2-8H2,1H3; Key:FSBMCTDYWXIBLM-UHFFFAOYSA-N;

Romaciclib is an investigational new drug being evaluated by Ryvu Therapeutics for the treatment of acute myeloid leukaemia (AML). It is a dual inhibitor of CDK8 and CDK19.^[1]^[2]^[3]

References

↑ "Romaciclib - Ryvu Therapeutics". AdisInsight. Springer Nature Switzerland AG.
↑ Rajendra A, Yee KW (April 2026). "Clinical development of a CDK8/19 kinase inhibitor for acute myeloid leukemia". Expert Opinion on Investigational Drugs. 35 (4): 253–256. doi:10.1080/13543784.2026.2656430. PMID 41931045.
↑ Pakulska U, Obacz M, Woźnicki J, Wiklik K, Chakraborty S, Micek M, et al. (January 2026). "Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy". bioRxiv 10.64898/2025.12.16.693978.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.